Martin Pronovost

Martin Pronovost, MBA, has a diverse work experience spanning over two decades. Currently, they serve as a Senior Project & Sales Manager at Tecniplast starting in 2022. In this role, they are responsible for promoting the company's vivarium equipment portfolio to various research institutes and biotech organizations across Quebec and Atlantic Canada. Additionally, Martin handles project management, equipment installations, and commissioning on an ad hoc basis.

Prior to their current position, Martin worked as a Senior Account Manager for Charles River Laboratories from 2016 to 2022. During this time, they managed key accounts and played a vital role in business development in Canada.

Before joining Charles River Laboratories, Martin held the role of Senior Rare Disease Business Manager for Cardiology at Aegerion Pharmaceuticals from 2014 to 2016. In this position, they focused on the Eastern Canadian market, showcasing their expertise in rare disease management.

Martin's experience also includes their tenure as a Rare Disease Business Manager for Neurology at Santhera Pharmaceuticals from 2009 to 2013. Here, they demonstrated their proficiency in the pharmaceutical industry, specializing in neurology and rare diseases in the Eastern Canadian region.

Early in their career, Martin worked as an Associate Sales Representative at Janssen-Ortho from 2004 to 2008, where they gained valuable experience in sales and pharmaceuticals.

Overall, with their extensive experience in sales, account management, and rare disease business management, Martin Pronovost proves to be a valuable asset in the pharmaceutical and biomedical industries.

Martin Pronovost, MBA has a diverse education history. In 1998, they started their higher education journey at Concordia University, where they pursued a Bachelor of Commerce degree with a focus on Finance. After completing their undergraduate studies in 2001, they further enhanced their financial knowledge by acquiring the Canadian Securities Course from the Canadian Securities Institute the same year.

In 2007, Martin attended the Council for Continuing Pharmaceutical Education (CCPE) to expand their expertise in Pharmacology and Biology through an Accreditation Course. Continuing their interest in the pharmaceutical field, they enrolled at the CCPE again in 2010 to study Health Care in Canada, broadening their understanding of the healthcare industry.

To further develop their business acumen, Martin pursued a Master of Business Administration (MBA) degree at HEC Montréal from 2008 to 2009. This program allowed him to specialize in Finance and Marketing, acquiring a comprehensive understanding of these disciplines.

In 2011, Martin attended the Council for Continuing Pharmaceutical Education (CCPE) once more, this time focusing on Pharmacoeconomics, which delves into the economic evaluation of pharmaceutical products.

Finally, in 2012, Martin pursued a special course called "Quantitative Methods in Clinical and Public Health Research" at the prestigious Harvard T.H. Chan School of Public Health. This course, conducted on the EDX campus, enhanced their proficiency in quantitative research methods specifically tailored for clinical and public health applications.

Martin Pronovost, MBA has demonstrated a commitment to their education by seeking various specialized courses and degrees across different fields, emphasizing finance, pharmaceuticals, healthcare, and business administration.